Safety and Efficacy Study of the Use of Sodium Pyruvate Bronchodilation in Asthmatics

2014-08-27 03:47:17 | BioPortfolio


Sodium pyruvate in sodium chloride solution will be delivered by nebulization to the lungs. It is believed that this administration will produce bronchodilation in asthmatics as determined by improvement in FEV1. FEV1 is a measure of lung function, and will be determined after administration of sodium pyruvate. The study is a blinded, so subjects may receive either the sodium pyruvate or a sodium chloride placebo. The primary endpoint will be the improvement of FEV1 after 15 minutes in subjects receiving sodium pyruvate compared to the FEV1 of subjects receiving the sodium chloride placebo.


Sodium Pyruvate, an intermediate metabolite, has been investigated as a therapeutic agent to reduce reactive oxygen species in the lung. Evaluation of FEV1 as a safety parameter and sequela of reactive oxygen species reduction identified inhaled Sodium Pyruvate as a potential bronchodilator.

A number of lung diseases are typically characterized by marked inflammation at the site of the lung injury. This inflammatory process leads to further destruction of surrounding healthy lung tissue, and a continuation and expansion of the sites of inflammation. This inflammatory process results in the production of reactive oxygen species, including superoxide anions and hydrogen peroxide, at the site of inflammation.

Nitric oxide is a known bronchodilator, as well as a vasodilator. It has been used successfully used to treat patients with various pulmonary disorders. 1 When endogenous nitric oxide is exposed to oxygen radicals, however, it is converted to the toxic oxidant nitrogen dioxide, and its bronchodilating effect is mitigated. Conversely, nitrogen dioxide is a known deep lung irritant. Its adverse consequences include the following: pulmonary inflammation; reduced levels of lung antioxidants 2; impairment of respiratory defense mechanisms leading to increased susceptibility to respiratory pathogens 3 and increased incidence and severity of respiratory infections; reduced lung function, and increased asthma and COPD symptoms.

Reactive oxygen species, especially superoxide anions, are known to compromise lung function by increasing bronchoconstriction. As a result of the increasing inflammation and the production of reactive oxygen species, and the decrease in nitric oxide that is believed to occur with the interstitial lung diseases, healthy tissue is damaged and lung function is compromised.

Based on our present understanding of the disease process involved with these lung diseases, it appears that an intervention in the inflammatory process that would result in a reduction in reactive oxygen species and a subsequent increase in nitric oxide could be an effective way to intervene in the disease process. This intervention would prevent the further spread of inflammation and lung damage caused by the production of reactive oxygen species, such as superoxide anions and hydrogen peroxide, and increase lung function by increasing bronchodilation.

Sodium pyruvate is a reactive oxygen species antagonist that has been shown to neutralize oxygen radicals, specifically lowering the overproduction of superoxide anions, regulate the production and level of other inflammatory mediators, and increase the synthesis of nitric oxide. 4 Sodium pyruvate also increases cellular levels of glutathione, a major cellular antioxidant, which is reduced dramatically in antigen-induced lung disease patients. 5

In pilot studies in mild asthmatic subjects, it was demonstrated that inhalation of low doses (0.5 mM) of nebulized sodium pyruvate decreased expired hydrogen peroxide by 30% at four hours compared to inhalation of a nebulized saline control. These subjects also experienced increased pulmonary function as determined by FEV1 (+12.8%) and PEF (+34.5%) measurements after four hours (referenced in Cellular Sciences IND #50,089). It is theorized that the reactive oxygen species antagonist properties of sodium pyruvate reduced the production of oxygen radicals, including hydrogen peroxide, and increased the levels of nitric oxide. Together, this led to reduced inflammation and lung damage, and increased lung function through improved bronchodilation.

In summary, it is believed that inhalation of sodium pyruvate will reduce the lung damage resulting from the increase in reactive oxygen species associated with the inflammation component of the disease, and will enhances the availability of nitric oxide to produce bronchodilation by enhancing its synthesis and protecting it from destruction by reactive oxygen species.

Experimental Clinical Protocol Hypothesis: Sodium Pyruvate delivered by nebulization to the lungs produces bronchodilation in asthmatics as measured by FEV1

Intent: Provide support for further drug development of nebulized Sodium Pyruvate as a therapeutic agent in asthma

Design Randomized, double-blind, placebo-controlled cross-over study of 52 completed subjects

Treatment 1: 0.5 mM sodium pyruvate in 0.9% saline solution, (5ml) (Cellular Sciences, CA) nebulized via a Pari LC Plus reusable nebulizer powered by a ProNeb compressor (Midlothian, VA) Treatment 2: Saline 0.9%, (5ml) (Baxter) nebulized using the same nebulizer system as above A randomization algorithm using random permuted blocks (4-8 subjects) will be used to generate treatment order assignments. An unblinded statistician will generate this list of treatment order assignments.

Patient Recruitment and Selection The large cohort of potential subjects who have previously participated in asthma studies through our clinical research laboratory will be apprised of the study. Patients attending the UCLA Asthma and Cough Center will also be informed of the study. Advertisements will be sent by regular mail and by e-mail to physicians participating in the UCLA Healthcare System and to local pulmonologists practicing throughout the Los Angeles area. Local Allergists who collaborate with us in common clinical trial protocols will be informed of the study by personalized letter and e-mail. Advertisements will be placed in the classified and/or health sections of local newspapers. A description of the study will be posted on internet sites featuring clinical research trials.

Subjects will be recruited until a total of 52 complete the study. Assuming a 5% drop-out and non-compliance rate, we expect a total of 55 subjects recruited Patient Eligibility Criteria

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Mild to Moderate Asthma


sodium pyruvate


David Geffen School of Medicine, UCLA
Los Angeles
United States


Active, not recruiting



Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:47:17-0400

Clinical Trials [3576 Associated Clinical Trials listed on BioPortfolio]

Sodium Pyruvate Therapy in COPD Patients

In animal models, sodium pyruvate has been shown to be an effective anti-inflammatory agent, and in human studies sodium pyruvate has been shown to be a bronchodilating agent. Subjects wit...

Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.

It is hypothesized that the inhalation of sodium pyruvate will reduce lung damage in patients with Cystic Fibrosis (CF) by its ability to reduce levels of toxic reactive oxygen and nitroge...

A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.

The primary objective of this study is to assess the safety of inhaled sodium pyruvate in people with Cystic Fibrosis (CF). Further, to determine whether inhaled sodium pyruvate will impro...

Inflammation and Corticosteroid Responsiveness in Severe Asthma

Some patients with mild asthma may develop severe asthma. It is not known what makes patients with mild asthma become severe, and we plan to find out why this happens. Patients with sever...

Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Allergic Asthma

This is a pivotal, 12-month, randomized, sham controlled, parallel group, multicenter, double blind study with an allocation ratio of 1:1. The study population is children between the ages...

PubMed Articles [6767 Associated PubMed Articles listed on BioPortfolio]

Improving efficiency of pediatric emergency asthma treatment by using metered dose inhaler.

Evidence suggests using metered dose inhaler (MDI) to treat acute asthma in the Emergency Department reduces length of stay, though methods of implementation are lacking. We modified a treatment pathw...

Human leukocyte antigen-G 3' untranslated region polymorphisms are associated with asthma severity.

Asthma is a genetically complex chronic inflammatory airway disorder, and according to disease pathogenesis, clinical manifestations may vary according to asthma severity. A gene region close to the h...

Advances in the treatment of mild asthma: recent evidence.

Asthma affects about 300 million individuals worldwide. Although most patients have mild disease, the majority of them do not have good control and are at risk of exacerbations. Poor compliance with r...

Relationship between Serum Level of Endocan and Severity of Childhood Asthma.

Endocan is an endothelial cell-associated proteoglycan that is preferentially expressed by renal and pulmonary endothe¬lium. It reflects endothelial activation and dysfunction, this study aimed to in...

Effect of inhaled corticosteroids on serum periostin levels in adult patients with mild-moderate asthma.

Periostin is an extracellular matrix protein, and its expression is upregulated in airway epithelial cells in patients with bronchial asthma. Periostin may be a key molecule linked to type 2 T-helper ...

Medical and Biotech [MESH] Definitions

Hereditary disorders of pyruvate metabolism. They are difficult to diagnose and describe because pyruvate is a key intermediate in glycolysis, gluconeogenesis, and the tricarboxylic acid cycle. Some inherited metabolic disorders may alter pyruvate metabolism indirectly. Disorders in pyruvate metabolism appear to lead to deficiencies in neurotransmitter synthesis and, consequently, to nervous system disorders.

A multienzyme complex responsible for the formation of ACETYL COENZYME A from pyruvate. The enzyme components are PYRUVATE DEHYDROGENASE (LIPOAMIDE); dihydrolipoamide acetyltransferase; and LIPOAMIDE DEHYDROGENASE. Pyruvate dehydrogenase complex is subject to three types of control: inhibited by acetyl-CoA and NADH; influenced by the energy state of the cell; and inhibited when a specific serine residue in the pyruvate decarboxylase is phosphorylated by ATP. PYRUVATE DEHYDROGENASE (LIPOAMIDE)-PHOSPHATASE catalyzes reactivation of the complex. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed)

ATP:pyruvate 2-O-phosphotransferase. A phosphotransferase that catalyzes reversibly the phosphorylation of pyruvate to phosphoenolpyruvate in the presence of ATP. It has four isozymes (L, R, M1, and M2). Deficiency of the enzyme results in hemolytic anemia. EC

A broad-spectrum penicillin antibiotic used orally in the treatment of mild to moderate infections by susceptible gram-positive organisms.

A pyrazole that has analgesic, anti-inflammatory, and antipyretic properties. It has been used in mild to moderate pain, fever, and inflammation associated with musculoskeletal and joint disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p15)

More From BioPortfolio on "Safety and Efficacy Study of the Use of Sodium Pyruvate Bronchodilation in Asthmatics"

Quick Search


Relevant Topics

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...

Searches Linking to this Trial